- Home
- BBIO vs LAZ Comparison
BBIO vs LAZ Comparison
Compare BBIO & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- LAZ
- Stock Information
- Founded
- BBIO 2015
- LAZ 1848
- Country
- BBIO United States
- LAZ United States
- Employees
- BBIO N/A
- LAZ N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- LAZ Investment Managers
- Sector
- BBIO Health Care
- LAZ Finance
- Exchange
- BBIO Nasdaq
- LAZ Nasdaq
- Market Cap
- BBIO 4.9B
- LAZ 5.3B
- IPO Year
- BBIO 2019
- LAZ 2005
- Fundamental
- Price
- BBIO $23.24
- LAZ $57.11
- Analyst Decision
- BBIO Strong Buy
- LAZ Hold
- Analyst Count
- BBIO 13
- LAZ 7
- Target Price
- BBIO $46.92
- LAZ $53.00
- AVG Volume (30 Days)
- BBIO 1.7M
- LAZ 905.0K
- Earning Date
- BBIO 11-12-2024
- LAZ 10-31-2024
- Dividend Yield
- BBIO N/A
- LAZ 3.53%
- EPS Growth
- BBIO N/A
- LAZ N/A
- EPS
- BBIO N/A
- LAZ 2.55
- Revenue
- BBIO $217,765,000.00
- LAZ $3,047,514,000.00
- Revenue This Year
- BBIO $3,690.39
- LAZ $14.99
- Revenue Next Year
- BBIO N/A
- LAZ $13.14
- P/E Ratio
- BBIO N/A
- LAZ $22.21
- Revenue Growth
- BBIO 2209.77
- LAZ 25.34
- 52 Week Low
- BBIO $21.62
- LAZ $27.14
- 52 Week High
- BBIO $44.32
- LAZ $61.14
- Technical
- Relative Strength Index (RSI)
- BBIO 41.84
- LAZ 60.41
- Support Level
- BBIO $21.72
- LAZ $54.30
- Resistance Level
- BBIO $27.57
- LAZ $56.21
- Average True Range (ATR)
- BBIO 1.42
- LAZ 1.91
- MACD
- BBIO -0.23
- LAZ -0.17
- Stochastic Oscillator
- BBIO 25.98
- LAZ 58.32
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About LAZ Lazard Inc.
Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.